ARMISTICE CAPITAL LLC 13D and 13G filings for Supernus Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 5:14 pm Purchase | 2024-09-30 | 13G | Supernus Pharmaceuticals, Inc. SUPN | ARMISTICE CAPITAL LLC | 5,096,000 9.250% | 446,000 (+9.59%) | Filing |
| 2024-02-14 2:33 pm Purchase | 2023-12-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN | ARMISTICE CAPITAL LLC | 4,650,000 8.510% | 294,000 (+6.75%) | Filing |
| 2023-02-14 1:33 pm Purchase | 2022-12-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN | ARMISTICE CAPITAL LLC | 4,356,000 8.060% | 220,000 (+5.32%) | Filing |
| 2022-02-14 7:03 pm Purchase | 2021-12-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN | ARMISTICE CAPITAL LLC | 4,136,000 7.800% | 1,016,000 (+32.56%) | Filing |
| 2021-02-16 5:00 pm Purchase | 2020-12-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN | ARMISTICE CAPITAL LLC | 3,120,000 5.900% | 232,000 (+8.03%) | Filing |
| 2020-03-12 5:13 pm Purchase | 2020-03-02 | 13G | Supernus Pharmaceuticals, Inc. SUPN | ARMISTICE CAPITAL LLC | 2,888,000 5.500% | 2,888,000 (New Position) | Filing |